BR112014004267A2 - derivado de ácido pirrolidina-3-ilacético - Google Patents
derivado de ácido pirrolidina-3-ilacéticoInfo
- Publication number
- BR112014004267A2 BR112014004267A2 BR112014004267A BR112014004267A BR112014004267A2 BR 112014004267 A2 BR112014004267 A2 BR 112014004267A2 BR 112014004267 A BR112014004267 A BR 112014004267A BR 112014004267 A BR112014004267 A BR 112014004267A BR 112014004267 A2 BR112014004267 A2 BR 112014004267A2
- Authority
- BR
- Brazil
- Prior art keywords
- substituent group
- group
- unsubstituted
- substituents selected
- pyrrolidine
- Prior art date
Links
- OUENRUZPZZFMCA-UHFFFAOYSA-N 2-pyrrolidin-1-ium-3-ylacetate Chemical class OC(=O)CC1CCNC1 OUENRUZPZZFMCA-UHFFFAOYSA-N 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 10
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
resumo derivado de ácido pirrolidina-3-ilacético trata-se de um composto representado pela fórmula (1) ou um sal farmaceuticamente aceitável do mesmo que tem um efeito inibidor na trajetória de fractalcina-cx3cr1: em que r representa um grupo alquila c1-c6 não substituído ou que tem 1 a 3 substituintes selecionados a partir de grupo substituinte a, um grupo cicloalquila c3-8 não substituído ou que tem 1 a 3 substituintes selecionados a partir de grupo substituinte a, ou um grupo cicloalquenila c3-8 não substituído ou que tem 1 a 3 substituintes selecionados a partir de grupo substituinte a, x representa um grupo alquila c1-c6, y e z são iguais ou diferentes entre si e cada um representa um átomo de halogênio ou um grupo alquila c1-c6 não substituído ou que tem 1 a 3 substituintes selecionados a partir de grupo substituinte b, n representa 0 ou 1, grupo substituinte a consiste em átomos de halogênio, e grupo substituinte b consiste em átomos de halogênio.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011199482 | 2011-09-13 | ||
| JP2011-199482 | 2011-09-13 | ||
| PCT/JP2012/073171 WO2013039057A1 (ja) | 2011-09-13 | 2012-09-11 | ピロリジン－３－イル酢酸誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014004267A2 true BR112014004267A2 (pt) | 2017-03-21 |
| BR112014004267B1 BR112014004267B1 (pt) | 2021-11-16 |
Family
ID=47883287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014004267-5A BR112014004267B1 (pt) | 2011-09-13 | 2012-09-11 | Derivado de ácido pirrolidina-3-ilacético |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP2757103B1 (pt) |
| JP (1) | JP5829689B2 (pt) |
| KR (1) | KR101963922B1 (pt) |
| CN (1) | CN103764648B (pt) |
| AR (1) | AR087788A1 (pt) |
| AU (1) | AU2012309556B2 (pt) |
| BR (1) | BR112014004267B1 (pt) |
| CA (1) | CA2844617C (pt) |
| CL (1) | CL2014000484A1 (pt) |
| CY (1) | CY1117460T1 (pt) |
| DK (1) | DK2757103T3 (pt) |
| ES (1) | ES2564732T3 (pt) |
| HK (1) | HK1193407A1 (pt) |
| HR (1) | HRP20160166T1 (pt) |
| HU (1) | HUE026824T2 (pt) |
| IL (1) | IL230804A (pt) |
| JO (1) | JO3082B1 (pt) |
| ME (1) | ME02383B (pt) |
| MX (1) | MX358494B (pt) |
| MY (1) | MY169869A (pt) |
| PE (1) | PE20141353A1 (pt) |
| PL (1) | PL2757103T3 (pt) |
| PT (1) | PT2757103E (pt) |
| RS (1) | RS54582B1 (pt) |
| RU (1) | RU2615135C2 (pt) |
| SG (1) | SG11201400163WA (pt) |
| SI (1) | SI2757103T1 (pt) |
| SM (1) | SMT201600071B (pt) |
| TW (1) | TWI543975B (pt) |
| UA (1) | UA112873C2 (pt) |
| WO (1) | WO2013039057A1 (pt) |
| ZA (1) | ZA201400918B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9550732B2 (en) | 2013-03-12 | 2017-01-24 | Eisai R&D Management Co., Ltd. | Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof |
| WO2014142086A1 (ja) * | 2013-03-13 | 2014-09-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピロリジン－３－イル酢酸誘導体およびピペリジン－３－イル酢酸誘導体 |
| WO2024083933A1 (en) | 2022-10-19 | 2024-04-25 | Astrazeneca Ab | 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3cr1 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4263391B2 (ja) | 2001-03-19 | 2009-05-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用 |
| US20050143372A1 (en) * | 2001-10-30 | 2005-06-30 | Shomir Ghosh | Compounds, pharmaceutical compositions and methods of use therefor |
| US20070142386A1 (en) * | 2003-10-07 | 2007-06-21 | Astrazeneca | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| AR053347A1 (es) * | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| TW200820973A (en) | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| WO2008039139A1 (en) | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy |
| CL2007002958A1 (es) * | 2006-10-12 | 2008-05-09 | Epix Delaware Inc | Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr |
| PL2262777T3 (pl) * | 2008-03-07 | 2016-08-31 | Acraf | Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1 |
| AR071036A1 (es) | 2008-03-26 | 2010-05-19 | Astrazeneca Ab | Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1. |
-
2012
- 2012-09-05 TW TW101132401A patent/TWI543975B/zh not_active IP Right Cessation
- 2012-09-05 JO JOP/2012/0251A patent/JO3082B1/ar active
- 2012-09-06 AR ARP120103280A patent/AR087788A1/es active IP Right Grant
- 2012-09-11 RU RU2014107536A patent/RU2615135C2/ru active
- 2012-09-11 MY MYPI2014700213A patent/MY169869A/en unknown
- 2012-09-11 CA CA2844617A patent/CA2844617C/en active Active
- 2012-09-11 BR BR112014004267-5A patent/BR112014004267B1/pt not_active IP Right Cessation
- 2012-09-11 JP JP2013533669A patent/JP5829689B2/ja not_active Expired - Fee Related
- 2012-09-11 SG SG11201400163WA patent/SG11201400163WA/en unknown
- 2012-09-11 PE PE2014000266A patent/PE20141353A1/es active IP Right Grant
- 2012-09-11 ES ES12831085.1T patent/ES2564732T3/es active Active
- 2012-09-11 DK DK12831085.1T patent/DK2757103T3/en active
- 2012-09-11 SI SI201230463T patent/SI2757103T1/sl unknown
- 2012-09-11 RS RS20160106A patent/RS54582B1/en unknown
- 2012-09-11 AU AU2012309556A patent/AU2012309556B2/en not_active Ceased
- 2012-09-11 KR KR1020147003630A patent/KR101963922B1/ko active IP Right Grant
- 2012-09-11 WO PCT/JP2012/073171 patent/WO2013039057A1/ja active Application Filing
- 2012-09-11 MX MX2014002210A patent/MX358494B/es active IP Right Grant
- 2012-09-11 EP EP12831085.1A patent/EP2757103B1/en active Active
- 2012-09-11 PT PT128310851T patent/PT2757103E/pt unknown
- 2012-09-11 CN CN201280041634.0A patent/CN103764648B/zh not_active Expired - Fee Related
- 2012-09-11 ME MEP-2016-37A patent/ME02383B/me unknown
- 2012-09-11 HU HUE12831085A patent/HUE026824T2/en unknown
- 2012-09-11 PL PL12831085T patent/PL2757103T3/pl unknown
- 2012-11-09 UA UAA201401661A patent/UA112873C2/uk unknown
-
2014
- 2014-02-03 IL IL230804A patent/IL230804A/en active IP Right Grant
- 2014-02-06 ZA ZA2014/00918A patent/ZA201400918B/en unknown
- 2014-02-27 CL CL2014000484A patent/CL2014000484A1/es unknown
- 2014-07-04 HK HK14106800.1A patent/HK1193407A1/xx not_active IP Right Cessation
-
2016
- 2016-02-16 HR HRP20160166TT patent/HRP20160166T1/hr unknown
- 2016-03-10 SM SM201600071T patent/SMT201600071B/xx unknown
- 2016-03-16 CY CY20161100224T patent/CY1117460T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016002083A2 (pt) | composto tetrazolinona e uso para o mesmo | |
| BR112018006292A2 (pt) | ?composição fungicida para uso agrícola e hortícola? | |
| BR112014001018A2 (pt) | derivado de azabenzimidazol tendo atividade de ativação de ampk | |
| MY176803A (en) | Polymorph of syk inhibitors | |
| RS53292B (en) | CRYSTAL FORMS 2-THIAZOLYL-4-HINOLINYL-OXY DERIVATIVES, POWERFUL HCV INHIBITOR | |
| BR112012033013A2 (pt) | composição de controle de doenças de plantas e método de controle de doenças de plantas | |
| BR112017009168A2 (pt) | derivado de tionucleosídeo ou sal deste e composição farmacêutica | |
| RS54526B1 (en) | USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS | |
| MA38583A1 (fr) | Dérivés de dolastatine 10 et d'auristatines | |
| CR20150663A (es) | Derivados de diazacarbazol como ligandos de tau para pet | |
| BRPI1009212B8 (pt) | Composto de piperazina capaz de inibir a prostaglandina d sintase, seus usos e composição farmacêutica | |
| MY194307A (en) | Pyridone derivative having tetrahydropyranylmethyl group | |
| BR112014028718A2 (pt) | derivados de hidantoína como inibidores de kv3 | |
| BR112016002063A2 (pt) | composto de tetrazolinona e uso do mesmo | |
| BR112016001979A2 (pt) | composto de tetrazolinona e uso do mesmo | |
| BR112015023829A2 (pt) | composto de amidina e seu uso | |
| MA38645A1 (fr) | Nouveaux inhibiteurs de cyp17/antiandrogènes | |
| BR112014026198A2 (pt) | compostos pirazol como inibidores de sglt1 | |
| BR112015017740A2 (pt) | composto heterocíclico condensado | |
| BR112012031340A2 (pt) | derivados de cianoquinolina | |
| BR112013005823B8 (pt) | Compostos heterocíclicos para o tratamento ou prevenção de distúrbios causados pela neurotransmissão reduzida de serotonina, norefnefrina ou dopamina | |
| BR112014004267A2 (pt) | derivado de ácido pirrolidina-3-ilacético | |
| BR112014000594A2 (pt) | composição para o controle de pragas artrópodes e método para controlar pragas artrópodes | |
| BR112016011778A8 (pt) | pirazol fluorofenila, seus usos, e composição farmacêutica | |
| BR112015009988A2 (pt) | melhoramentos em compostos orgânicos ou relativos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/09/2012, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2791 DE 02-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |